BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from ...

Uncover the top 7 criteria for selecting a central lab for clinical trials phases. Optimize your research outcomes now with ...

Calls have emerged for a comprehensive redesign of the drug development system as delays in global Phase 2 and 3 clinical ...

Lumen Bioscience has announced positive results from the RePreve Clinical Trial of oral LMN-201, an investigational biologic cocktail drug, that demonstrate a statistically significant global cure and ...

MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...

Preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026, and total liabilities of approximately $2.5 million ...

HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory HQ-CT scores fell by Week 2 ...

Genialis, the therapeutic intelligence company, will present data at the European Society for Medical Oncology (ESMO) ...

Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume. Aardvark will host a webcast to ...

The Ibogaine Club Research Group, an independent research resource focused on ibogaine safety data and treatment center protocols, has submitted a formal public comment to the U.S. Food and Drug ...

With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ...